Oncology

Latest News

The investigators found that tumor mutational burden and PD-L1 expression, which have traditionally been used as indicators of immunotherapy efficacy, had little predictive value for survival in this cohort. | Image credit: Dragana Gordic - stock.adobe.com

Predictive Model Forecasts Advanced NSCLC Outcomes

By Jared Kaltwasser

August 14th 2025

The newly developed model has an area under the curve of 0.807 for predicting progression-free survival.

Dordaviprone is indicated for recurrent H3 K27M-mutant diffuse midline glioma, an ultra-rare, aggressive brain tumor primarily affecting children. | Image credit: wladimir1804 - stock.adobe.com

FDA Approves Dordaviprone as First and Only Treatment for Aggressive Form of Glioma

By Rose McNulty

August 6th 2025

Gen Li, PhD, MBA, president and founder of Phesi

Real-World Data, Digital Patient Profiles Are Revolutionizing Trial Design, Patient Recruitment: Gen Li, PhD, MBA

By Pearl Steinzor
Gen Li, PhD, MBA

August 4th 2025

Value-based care. | Image Credit: irissca - stock.adobe.com

Legal Navigation Services Key to Addressing Disparities in Cancer Care

By Cameron Santoro

July 31st 2025

Radiotherapy can work synergistically with immunotherapy by reprogramming the tumor microenvironment. | Image credit: Crystallight-stock.adobe.com

Brain Radiotherapy Plus ICIs Boost Survival in SCLC With Brain Metastases

By Jared Kaltwasser

July 30th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

View All

August 15th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

August 15th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

January 31st 2016

Early Palliative Care for Cancer Patients With More Comorbidities Reduces Cost

Priyam Vora

Providing cancer patients with multiple life-threatening conditions with earlier palliative care consultation can be helpful in bringing down healthcare spending in enormous proportions, according to a new study published in Health Affairs.

January 30th 2016

This Week in Managed Care: January 30, 2016

Top managed care news of the week includes new recommendation to screen all adults for depression, new issue of The American Journal of Managed Care places attention on mental health care, and Donald Trump calls for Medicare to negotiate drug prices.

January 30th 2016

Tbo-Filgrastim Can Replace Filgrastim During ASCT in Myeloma and Lymphoma

AJMC Staff

A study presented at the annual meeting of the American Society of Hematology concluded that tbo-filgrastim is similar to filgrastim for ASCT mobilization in patients with MM or NHL.

January 29th 2016

Study Identifies Disparity in Survival of AYA Hodgkin Lymphoma

Surabhi Dangi-Garimella, PhD

Mortality in adolescent and young adult Hodgkin lymphoma patients is significantly affected by ethnic and socioeconomic factors, as well as insurance status, according to a new study published in Cancer Epidemiology, Biomarkers & Prevention.

January 29th 2016

Do Hematologists Believe APMs Afford Fair Value? An Open Discussion at ASH

Surabhi Dangi-Garimella, PhD

At the annual meeting of the American Society of Hematology, physicians gathered to discuss the impact of alternate payment models on clinical practice.

January 29th 2016

Does Geographic Location Influence Healthcare Utilization in Children With Lymphoma?

Surabhi Dangi-Garimella, PhD

A study presented at the 57th meeting of the American Society of Hematology finds that distance from the site of care could could adversely affect outcomes in children with acute lymphoblastic leukemia and acute myeloid leukemia.

January 29th 2016

Healthcare Utilization in Children With Sickle Cell Disease

Surabhi Dangi-Garimella, PhD

At the annual meeting of the American Society of Hematology, researchers from the Aflac Cancer and Blood Disorders Center presented analysis evaluating the factors that influence health outcomes in children with sickle cell disease.

January 29th 2016

5 Things to Know About Clinical Pathways

Surabhi Dangi-Garimella, PhD

Learn where clinical care pathways stand today and what the future holds with respect to developing and implementing them.

January 28th 2016

FDA Advocates for Diversity in Clinical Trials

Surabhi Dangi-Garimella, PhD

The FDA has created the Drug Trial Snapshot, which provides details on the demographic profiles of participants in clinical trials of approved drugs.

January 28th 2016

Three Proposals That Would Kill the 340B Program

Robert Chapman, MD

The 3 prescriptions for reforming the 340B Drug Discount Program proposed by authors in the December issue of Evidence-Based Oncology would limit safety net hospitals' abilities to treat vulnerable patients.

January 28th 2016

Nivolumab Improved OS in SCCHN; CheckMate-141 Stopped Early

Surabhi Dangi-Garimella, PhD

A review by an independent Data Monitoring Committee found that nivolumab improved overall survival in patients with squamous cell carcinoma of the head and neck, compared with the control arm.

January 27th 2016

Study Shows Academic Hospitals Better at Caring for ALL Patients

Surabhi Dangi-Garimella, PhD

A study presented during a health outcomes session at the American Society of Hematology meeting evaluated the difference in overall survival in patients with acute lymphoblastic leukemia treated in academic versus nonacademic hospitals.

January 27th 2016

Insurance Status Determines OS in Patients With CML

Surabhi Dangi-Garimella, PhD

Results presented at the annual meeting of the American Society of Hematology found that many patients diagnosed with chronic myeloid leukemia may not have access to or receive appropriate care, in part due to their insurance coverage.

January 27th 2016

Importance of Patient-Reported Outcomes and Quality-of-Life Measures in Myeloid Disease

Surabhi Dangi-Garimella, PhD

Results from a patient-reported outcomes measure of symptoms and symptom burden, experienced by patients with acute myeloid leukemia and myelodysplastic syndrome, were presented at the 57th annual meeting of the American Society of Hematology.

January 27th 2016

Smoking Can Reduce Survival of Breast Cancer Patients

Surabhi Dangi-Garimella, PhD

A study published in the Journal of Clinical Oncology has found that smoking before and after diagnosis of breast cancer is associated with increased mortality from breast cancer as well as other conditions, including respiratory and cardiovascular disease.

January 27th 2016

Study Finds Strongest Link Yet Between Tanning Beds and Cancer, Especially Among Teens

Mary Caffrey

The FDA seeks a nationwide ban on indoor tanning among those under 18. Right now, a patchwork of laws bar teens from indoor tanning in some states and require parental consent in others.

January 26th 2016

Personalizing Healthcare and Also Paying for It

Surabhi Dangi-Garimella, PhD

Personalized medicine has been the mantra in healthcare for quite some time, but finding health plans with blanket coverage policies for diagnostic testing is a struggle.

January 25th 2016

How Do You Develop, and Successfully Incorporate, PROs in Hematology? Experts Chime in at ASH

Surabhi Dangi-Garimella, PhD

An educational session on Patient-Reported Outcomes in Hematology at the annual meeting of the American Society of Hematology, discussed the importance of embracing the patient perspective in healthcare delivery.

January 25th 2016

Experts Share Concepts of Quality Measures and Pay-for-Performance With Hematologists

Surabhi Dangi-Garimella, PhD

At the annual meeting of the American Society of Hematology, experts discussed quality measurement, public performance reporting, and pay-for-performance and it's impact on healthcare in the United States.

January 25th 2016

ASH Leverages Recommendations From Other Medical Organizations, Advising Hematologists to Choose Wisely

Surabhi Dangi-Garimella, PhD

Thirteen hematologists on the American Society of Hematology(ASH)'s Choosing Wisely Task Force chose the top 5 of 380 recommendations listed by 70 other societies for presentation at ASH.

January 25th 2016

Cancer Study Recommends Lowering CRC Screening Age

Surabhi Dangi-Garimella, PhD

The authors of the study recommend lowering the screening age for colorectal cancer (CRC), especially for first-degree relatives of CRC patients and those with a genetic predisposition to the disease.

January 23rd 2016

This Week in Managed Care: January 23, 2016

Top managed care stories this week included UnitedHealth reporting larger-than-expected losses on Affordable Care Act health plans, new guidelines from the government that will improve patient access to medical records, and new information that can reduce risk of diabetes.

January 23rd 2016

Dr Kavital Patel Examines Accounting for Drug Costs in Total Cost of Care

Kavita Patel, MD, fellow in economic studies and managing director at Brookings Institution, discussed how the cost of drugs should be accounted for in the total cost of care, and the importance of considering patient needs when offering drugs.

January 22nd 2016

How Much Will Amgen's Carfilzomib for Multiple Myeloma Cost?

Surabhi Dangi-Garimella, PhD

Carfilzomib has been approved by the FDA for use in combination with dexamethasone or lenalidomide, in patients with relapsed/refractory multiple myeloma who have previously received 1 to 3 lines of therapy.

January 21st 2016

Abundant Optimism at the ASH/FDA Joint Symposium on New Drug Approvals in Multiple Myeloma

Surabhi Dangi-Garimella, PhD

At a joint session at the annual meeting of the American Society of Hematology, primary clinical reviewers from the FDA discussed the safety and efficacy issues of 3 very recently approved drugs for multiple myeloma, along with 2 clinicians who have extensive experience with these drugs in the real-world setting.

January 21st 2016

New Hematology Drugs: Progress and Challenges Discussed at the 57th ASH Meeting

Surabhi Dangi-Garimella, PhD

A session on the first day of the annual meeting of the American Society of Hematology, held December 5-8, 2015, in Orlando, Florida, clinicians discussed the promise and challenges of using newly approved hematology/oncology agents.

January 21st 2016

Surabhi Dangi-Garimella, PhD

An estimated 15.7% of individuals 65 or older may have received nonrecommended screenings for prostate and breast cancer, according to a new study published in JAMA Oncology.

January 21st 2016

ED-Initiated Palliative Care Can Improve Quality of Life

Jackie Syrop

Palliative care initiated in the emergency department for patients with advanced cancer improves quality of life without shortening survival.

January 21st 2016

Indoor Tanning Among Teens Associated With Drug Use, Study Finds

Mary Caffrey

The study found a stronger association than researchers expected; it appears that risky behavior in one area implies risky behavior elsewhere.

January 21st 2016

Novel Combinations in Multiple Myeloma and Lymphoma

Michael R. Page, PharmD, RPh Surabhi Dangi-Garimella, PhD

At the 57th annual meeting of the American Society of Hematology, oncologists discussed trial data evaluating combination therapies for multiple myeloma and lymphoma.

...

112 113 114 115 116 117 118 119 120

...

187 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions